Company news
Sight Sciences, Inc. (NASDAQ:SGHT) news
Sight Sciences, Inc. news releases on 6ix. Latest, Dec 22, 2021: Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment…
Press releases — page 3
Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
December 21, 2021
Sight Sciences Reports Third Quarter 2021 Financial Results
November 9, 2021
Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)
November 9, 2021
Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021
October 26, 2021
Sight Sciences Announces TearCare® Clinical Data Published in Cornea
October 19, 2021
Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement
September 15, 2021
Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma
August 23, 2021
Sight Sciences Reports Second Quarter 2021 Financial Results
August 11, 2021
Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021
August 1, 2021
Sight Sciences Announces Multiple Presentations at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
July 21, 2021
Sight Sciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
July 18, 2021
Sight Sciences Announces Pricing of Initial Public Offering
July 13, 2021